{"id":"https://openalex.org/W4389247243","doi":"https://doi.org/10.1182/blood-2023-188117","title":"Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy","display_name":"Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy","alternate_titles":[],"publication_year":2023,"publication_date":"2023-11-02","ids":{"openalex":"https://openalex.org/W4389247243","doi":"https://doi.org/10.1182/blood-2023-188117"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2023-188117","doi":"https://doi.org/10.1182/blood-2023-188117","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood-2023-188117","pdf_url":"https://ashpublications.org/blood/article-pdf/142/Supplement 1/1971/2200334/blood-8574-main.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4389247243"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ashpublications.org/blood/article-pdf/142/Supplement 1/1971/2200334/blood-8574-main.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113059695","display_name":"Priyanka Venkatesh","orcid":"https://orcid.org/0000-0001-5465-1595","observed_orcids":["https://orcid.org/0000-0001-5465-1595"]},"institutions":[{"id":"https://openalex.org/I4210128618","display_name":"University of Kansas Medical Center","ror":"https://ror.org/036c9yv20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210128618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Priyanka Venkatesh","raw_affiliation_strings":["1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","2Internal Medicine, The University of Kansas Medical Center, Kansas City, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","institution_ids":[]},{"raw_affiliation_string":"2Internal Medicine, The University of Kansas Medical Center, Kansas City, KS","institution_ids":["https://openalex.org/I4210128618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004567760","display_name":"Ghena Khasawneh","orcid":"https://orcid.org/0000-0002-1225-2905","observed_orcids":["https://orcid.org/0000-0002-1225-2905"]},"institutions":[{"id":"https://openalex.org/I156983542","display_name":"Jordan University of Science and Technology","ror":"https://ror.org/03y8mtb59","country_code":"JO","type":"education","lineage":["https://openalex.org/I156983542"]}],"countries":["JO"],"is_corresponding":false,"raw_author_name":"Ghena Khasawneh","raw_affiliation_strings":["1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","3Jordan University of Science and Technology, Irbid, Jordan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","institution_ids":[]},{"raw_affiliation_string":"3Jordan University of Science and Technology, Irbid, Jordan","institution_ids":["https://openalex.org/I156983542"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004973468","display_name":"Hamza Hashmi","orcid":"https://orcid.org/0000-0002-4129-5867","observed_orcids":["https://orcid.org/0000-0002-4129-5867"]},"institutions":[{"id":"https://openalex.org/I153297377","display_name":"Medical University of South Carolina","ror":"https://ror.org/012jban78","country_code":"US","type":"education","lineage":["https://openalex.org/I153297377"]},{"id":"https://openalex.org/I4210095449","display_name":"MUSC Hollings Cancer Center","ror":"https://ror.org/00w52vt71","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210095449"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hamza Hashmi","raw_affiliation_strings":["1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","4Hollings Cancer Center, Medical University of South Carolina, Charleston, SC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","institution_ids":[]},{"raw_affiliation_string":"4Hollings Cancer Center, Medical University of South Carolina, Charleston, SC","institution_ids":["https://openalex.org/I153297377","https://openalex.org/I4210095449"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056583873","display_name":"Omar Abed Alkharabsheh","orcid":"https://orcid.org/0000-0002-5299-4233","observed_orcids":["https://orcid.org/0000-0002-5299-4233"]},"institutions":[{"id":"https://openalex.org/I83809506","display_name":"University of South Alabama","ror":"https://ror.org/01s7b5y08","country_code":"US","type":"education","lineage":["https://openalex.org/I83809506"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Omar Alkharabsheh","raw_affiliation_strings":["1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","5University of South Alabama, Mobile, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","institution_ids":[]},{"raw_affiliation_string":"5University of South Alabama, Mobile, AL","institution_ids":["https://openalex.org/I83809506"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110814881","display_name":"Barry A. Paul","orcid":"https://orcid.org/0000-0003-2702-8225","observed_orcids":["https://orcid.org/0000-0003-2702-8225"]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barry Paul","raw_affiliation_strings":["1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","6Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","institution_ids":[]},{"raw_affiliation_string":"6Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC","institution_ids":["https://openalex.org/I4210100342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111658759","display_name":"Barry Skikne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210128618","display_name":"University of Kansas Medical Center","ror":"https://ror.org/036c9yv20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210128618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Barry S. Skikne","raw_affiliation_strings":["1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","7Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","institution_ids":[]},{"raw_affiliation_string":"7Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS","institution_ids":["https://openalex.org/I4210128618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025325121","display_name":"Zahra Mahmoudjafari","orcid":"https://orcid.org/0000-0002-3168-2521","observed_orcids":["https://orcid.org/0000-0002-3168-2521"]},"institutions":[{"id":"https://openalex.org/I4210128618","display_name":"University of Kansas Medical Center","ror":"https://ror.org/036c9yv20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210128618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zahra Mahmoudjafari","raw_affiliation_strings":["1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","7Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","institution_ids":[]},{"raw_affiliation_string":"7Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS","institution_ids":["https://openalex.org/I4210128618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088949367","display_name":"Nausheen Ahmed","orcid":"https://orcid.org/0000-0003-4336-4982","observed_orcids":["https://orcid.org/0000-0003-4336-4982"]},"institutions":[{"id":"https://openalex.org/I4210128618","display_name":"University of Kansas Medical Center","ror":"https://ror.org/036c9yv20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210128618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nausheen Ahmed","raw_affiliation_strings":["1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","7Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","institution_ids":[]},{"raw_affiliation_string":"7Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS","institution_ids":["https://openalex.org/I4210128618"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030746256","display_name":"Al-Ola A. Abdallah","orcid":"https://orcid.org/0000-0002-6603-185X","observed_orcids":["https://orcid.org/0000-0002-6603-185X"]},"institutions":[{"id":"https://openalex.org/I4210128618","display_name":"University of Kansas Medical Center","ror":"https://ror.org/036c9yv20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210128618"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Al-Ola Abdallah","raw_affiliation_strings":["1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","7Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","institution_ids":[]},{"raw_affiliation_string":"7Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS","institution_ids":["https://openalex.org/I4210128618"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042487436","display_name":"Shebli Atrash","orcid":"https://orcid.org/0000-0003-4547-7534","observed_orcids":["https://orcid.org/0000-0003-4547-7534"]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shebli Atrash","raw_affiliation_strings":["1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","6Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1US Myeloma Innovations Research Collaborative (USMIRC), Kansas City, KS","institution_ids":[]},{"raw_affiliation_string":"6Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC","institution_ids":["https://openalex.org/I4210100342"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5000,"currency":"USD","value_usd":5000},"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"142","issue":"Supplement 1","first_page":"1971","last_page":"1971"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9900000095367432},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.7649999856948853},{"id":"https://openalex.org/keywords/daratumumab","display_name":"daratumumab","score":0.8939999938011169},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9340000152587891},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.9269999861717224},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":0.9620000123977661},{"id":"https://openalex.org/keywords/cyclophosphamide","display_name":"cyclophosphamide","score":0.9620000123977661},{"id":"https://openalex.org/keywords/etoposide","display_name":"etoposide","score":0.9980000257492065},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.8960000276565552},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8550000190734863},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9679999947547913},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.4880000054836273},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8169999718666077},{"id":"https://openalex.org/keywords/real-world-outcomes","display_name":"real-world outcomes","score":0.49000000953674316}],"concepts":[{"id":"https://openalex.org/C2781119759","wikidata":"https://www.wikidata.org/wiki/Q5222113","display_name":"Daratumumab","level":4,"score":0.8471369743347168},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8295683264732361},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.7230597734451294},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6605002880096436},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.614444375038147},{"id":"https://openalex.org/C2778119113","wikidata":"https://www.wikidata.org/wiki/Q418817","display_name":"Etoposide","level":3,"score":0.5732128024101257},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.527479350566864},{"id":"https://openalex.org/C2780775027","wikidata":"https://www.wikidata.org/wiki/Q17141389","display_name":"Salvage therapy","level":3,"score":0.5143560171127319},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4837677478790283},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.4781576097011566},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.46405115723609924},{"id":"https://openalex.org/C2776063141","wikidata":"https://www.wikidata.org/wiki/Q425681","display_name":"Lenalidomide","level":3,"score":0.4390649199485779},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4160372018814087},{"id":"https://openalex.org/C2778367456","wikidata":"https://www.wikidata.org/wiki/Q7251235","display_name":"Proteasome inhibitor","level":3,"score":0.41236746311187744},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4030194878578186},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3086302578449249},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2023-188117","doi":"https://doi.org/10.1182/blood-2023-188117","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood-2023-188117","pdf_url":"https://ashpublications.org/blood/article-pdf/142/Supplement 1/1971/2200334/blood-8574-main.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1182/blood-2023-188117","doi":"https://doi.org/10.1182/blood-2023-188117","is_oa":true,"landing_page_url":"https://doi.org/10.1182/blood-2023-188117","pdf_url":"https://ashpublications.org/blood/article-pdf/142/Supplement 1/1971/2200334/blood-8574-main.pdf","source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4389247243.pdf","grobid_xml":"https://content.openalex.org/works/W4389247243.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389219644","https://openalex.org/W4389234829","https://openalex.org/W4391598521","https://openalex.org/W2889127703","https://openalex.org/W3211459408","https://openalex.org/W3110894725","https://openalex.org/W4389229181","https://openalex.org/W4405052354","https://openalex.org/W3087407267","https://openalex.org/W2980555132"],"abstract_inverted_index":null,"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4389247243","counts_by_year":[],"updated_date":"2026-11-18T13:11:19.462570","created_date":"2023-12-02T00:00:00"}
